Clinisys Completes Combination of Sunquest, HORIZON and ApolloLIMS Businesses

Clinisys today announces it has completed the combination of Sunquest Information Systems, HORIZON Lab Systems, and Apollo LIMS under its singular brand. The completion marks a new chapter for Clinisys, expanding its global presence and breadth of expertise to enable healthier communities through the transformation of the modern laboratory.

Clinisys is now one of the largest information systems providers for laboratories globally across healthcare, life sciences, and public health with over 3,000 customers in 34 countries.

Company CEO Michael Simpson, commented: “Combining the businesses gives us the scale to help tackle the biggest informatics challenges faced by laboratories today, helping to streamline workflows and improve the health and wellbeing of communities worldwide. We are committed to providing best-of-breed solutions to support every type of laboratory or remote testing environment; public or private sector, in-house or outsourced, and in all types of laboratory sectors, including Healthcare, Water, Crop Sciences, Contract Services, Life Sciences, Environmental, Food & Beverage, Pharma, and Public Health.”

“We are consolidating behind the Clinisys brand to signal our expanded support for a much wider range of industries and sectors, as well as global operations,” Simpson added. “As we look to the future, we will continue to invest in our core products and solutions from each of the combined businesses, as part of our long-term integrated Clinisys Laboratory Platform strategy. This means customers will benefit from continuity while tapping into our expanded capabilities and scale.”

For existing customers, the combination of the new businesses will not affect the existing products and services provided to them, which will now be delivered to them using the new Clinisys brand.

SourceClinisys

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”